AI Engines For more Details: Perplexity Kagi Labs You
Cardiovascular Health: Elevated levels of homocysteine in the blood have been associated with an increased risk of cardiovascular disease. NAHT has been investigated for its potential to lower homocysteine levels, thereby potentially reducing cardiovascular risk. However, research on the effectiveness of NAHT in this regard is limited, and more studies are needed to confirm its benefits.
Neurological Disorders: High levels of homocysteine have also been implicated in the pathogenesis of neurological disorders such as Alzheimer's disease, Parkinson's disease, and stroke. Some studies have suggested that NAHT may have neuroprotective effects and could potentially help mitigate the progression of these conditions. However, more research is needed to fully understand the impact of NAHT on neurological health.
Inflammation: Homocysteine is known to induce inflammation and oxidative stress, both of which are implicated in the development of various diseases. NAHT has been investigated for its potential anti-inflammatory properties, with some studies suggesting that it may help reduce inflammation and oxidative damage. However, further research is needed to elucidate the mechanisms underlying these effects and to determine their clinical significance.
Safety and Tolerability: NAHT has been found to be generally safe and well-tolerated in clinical studies. Adverse effects are typically mild and transient, although individual responses may vary. As with any medication, it's important to follow dosage instructions and consult with a healthcare professional if you experience any adverse reactions.
Rank | Probiotic | Impact |
---|---|---|
species | Escherichia coli | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
---|---|---|---|
ADHD | 0.1 | -0.1 | |
Allergic Rhinitis (Hay Fever) | 0.1 | 0.1 | |
Allergies | 0.3 | 0.3 | |
Allergy to milk products | 0.3 | 0.1 | 2 |
Alzheimer's disease | 0.1 | 0.2 | -1 |
Amyotrophic lateral sclerosis (ALS) Motor Neuron | 0.4 | 0.3 | 0.33 |
Ankylosing spondylitis | 0.4 | 0.1 | 3 |
Anorexia Nervosa | 0.1 | -0.1 | |
Antiphospholipid syndrome (APS) | 0.3 | 0.3 | |
Atrial fibrillation | 0.2 | 0.1 | 1 |
Autism | 0.3 | 0.5 | -0.67 |
benign prostatic hyperplasia | 0.1 | 0.1 | |
Bipolar Disorder | 0.1 | 0.1 | 0 |
Carcinoma | 0.1 | 0.1 | |
Celiac Disease | 0.3 | 0.1 | 2 |
Chronic Fatigue Syndrome | 0.1 | 0.4 | -3 |
Chronic Kidney Disease | 0.1 | 0.2 | -1 |
Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | -0.2 | |
Chronic Urticaria (Hives) | 0.4 | 0.4 | |
Coagulation / Micro clot triggering bacteria | 0.4 | 0.4 | |
Colorectal Cancer | 0.4 | 0.4 | |
Constipation | 0.2 | 0.2 | |
Coronary artery disease | 0.1 | -0.1 | |
COVID-19 | 0.4 | 0.3 | 0.33 |
Crohn's Disease | 0.6 | 0.4 | 0.5 |
cystic fibrosis | 0.4 | 0.4 | |
deep vein thrombosis | 0.4 | 0.4 | |
Depression | 0.6 | 0.5 | 0.2 |
Eczema | 0.1 | 0.1 | |
Endometriosis | 0.6 | 0.1 | 5 |
Epilepsy | 0.1 | 0.1 | |
Fibromyalgia | 0.2 | -0.2 | |
Functional constipation / chronic idiopathic constipation | 0.5 | 0.1 | 4 |
gallstone disease (gsd) | 0.1 | 0.1 | |
Generalized anxiety disorder | 0.4 | 0.1 | 3 |
Gout | 0.1 | -0.1 | |
Histamine Issues,Mast Cell Issue, DAO Insufficiency | 0.4 | 0.4 | |
hyperglycemia | 0.1 | 0.1 | |
hypertension (High Blood Pressure | 0.1 | 0.1 | 0 |
Hypothyroidism | 0.1 | -0.1 | |
IgA nephropathy (IgAN) | 0.2 | -0.2 | |
Inflammatory Bowel Disease | 0.4 | 0.2 | 1 |
Insomnia | 0.1 | -0.1 | |
Intelligence | 0.1 | 0.1 | |
Irritable Bowel Syndrome | 0.4 | 0.1 | 3 |
Liver Cirrhosis | 0.3 | 0.1 | 2 |
Long COVID | 0.5 | 0.4 | 0.25 |
Low bone mineral density | 0.2 | -0.2 | |
Lung Cancer | 0.1 | 0.1 | |
ME/CFS with IBS | 0.2 | -0.2 | |
ME/CFS without IBS | 0.1 | 0.1 | |
Metabolic Syndrome | 0.6 | 0.1 | 5 |
Mood Disorders | 0.7 | 0.5 | 0.4 |
Multiple Sclerosis | 0.2 | -0.2 | |
Neuropathy (all types) | 0.1 | -0.1 | |
neuropsychiatric disorders (PANDAS, PANS) | 0.3 | 0.3 | |
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 0.1 | 0.2 | -1 |
Obesity | 0.3 | 0.1 | 2 |
obsessive-compulsive disorder | 0.5 | 0.1 | 4 |
Osteoarthritis | 0.1 | 0.1 | |
Osteoporosis | 0.1 | 0.1 | |
Parkinson's Disease | 0.4 | 0.4 | 0 |
Polycystic ovary syndrome | 0.1 | 0.1 | |
Postural orthostatic tachycardia syndrome | 0.1 | -0.1 | |
Psoriasis | 0.3 | 0.1 | 2 |
rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 0.4 | 0.1 | 3 |
Schizophrenia | 0.2 | 0.1 | 1 |
scoliosis | 0.1 | 0.2 | -1 |
Sjögren syndrome | 0.1 | 0.1 | |
Sleep Apnea | 0.1 | 0.1 | 0 |
Small Intestinal Bacterial Overgrowth (SIBO) | 0.3 | 0.3 | |
Stress / posttraumatic stress disorder | 0.3 | 0.1 | 2 |
Systemic Lupus Erythematosus | 0.3 | 0.1 | 2 |
Type 1 Diabetes | 0.3 | 0.1 | 2 |
Type 2 Diabetes | 0.6 | 0.4 | 0.5 |
Ulcerative colitis | 0.4 | 0.1 | 3 |
Unhealthy Ageing | 0.1 | 0.1 | 0 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.